STOCK TITAN

Purple Biotech Ltd - PPBT STOCK NEWS

Welcome to our dedicated news page for Purple Biotech (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Purple Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Purple Biotech's position in the market.

Rhea-AI Summary
Purple Biotech Ltd. announces positive clinical results for NT219 in combination with cetuximab in the treatment of head and neck cancer. The Phase 1/2 study showed a well-tolerated safety profile, with a 29% Objective Response Rate and 71% Disease Control Rate. NT219 demonstrated anti-tumor activity at higher dose levels, especially in HPV negative patients, supporting further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Purple Biotech Ltd. announced the establishment of the recommended dose for NT219 with demonstrated anti-tumor activity. The company convened a Scientific Advisory Board focusing on NT219's indication in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Prominent key opinion leaders provided insights on clinical studies for NT219 in combination with cetuximab and potentially a PD1 inhibitor. Purple Biotech is ready to move to the next phase of development with the support of the SAB members.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management clinical trial
-
Rhea-AI Summary
Purple Biotech Ltd. announces the recommended Phase 2 dose for NT219 in combination with cetuximab for the treatment of head and neck cancer. The company reported dose-dependent anti-tumor activity with confirmed partial responses and no dose-limiting toxicities. Detailed clinical results from the dose escalation portion of the study will be presented at the ESMO TAT Congress 2024 in Paris.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
clinical trial
Rhea-AI Summary
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) appoints Dr. Yael Margolin, a biotech and pharma expert, as an independent member of the Board of Directors. Dr. Margolin brings 35 years of experience and has served in leadership roles in various healthtech companies. The company also announces the resignation of Mr. Fabien Sebille, the Chief Business Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.18%
Tags
management
-
Rhea-AI Summary
Purple Biotech Ltd. (PPBT) completes patient enrollment in Phase 2 study of CM24, a multi-functional immune checkpoint inhibitor, for pancreatic cancer treatment. Interim analysis of overall survival expected in 1H 2024 and topline analysis in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
clinical trial
-
Rhea-AI Summary
Purple Biotech Ltd. (PPBT) announced positive results for the NT219 Phase 1/2 study in head and neck cancer, with patient enrollment in the Phase 2 CM24 Pancreatic Cancer trial ahead of schedule. The company's cash runway has been extended to the second half of 2025 through recent financing. Financial results for Q3 2023 show an increase in research and development expenses, with a net loss of $5 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
earnings
Rhea-AI Summary
Purple Biotech has been granted a new patent in China for maintaining a pharmaceutical composition of NT219 in its active form. The patent protects the method of preventing the conversion of NT219 from its active form to a less active form and supports the maintenance of the active form during manufacturing, storage, and handling. This expands Purple Biotech's patent protection for NT219 in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
-
Rhea-AI Summary
Purple Biotech closes registered direct offering, raising approximately $5 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
offering
-
Rhea-AI Summary
Purple Biotech announces purchase and sale agreement for 4,347,827 ADSs at $1.15 per ADS in a registered direct offering. Concurrent private placement includes unregistered warrants to purchase up to 4,347,827 ADSs at $1.25 per ADS. Gross proceeds expected to be approximately $5 million. Proceeds will be used for development of oncology therapeutic candidates and general working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
offering
Rhea-AI Summary
Purple Biotech reports new biomarker data for CM24 oncology drug at AACR conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
Purple Biotech Ltd

Nasdaq:PPBT

PPBT Rankings

PPBT Stock Data

18.41M
183.10M
4.08%
9.44%
1.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
132 Menachem Begin Road

About PPBT

kitov pharmaceuticals ltd. is a financial services company located in israel.